CRISPR Therapeutics AG
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of CRISPR Therapeutics AG generated cash of -$260,375,000, which is more than the previous year. Cash used in financing activities reached the amount of $62,664,000 last year. Net change in cash is therefore $177,008,000.
Cash Flow
| 2014 | -4.79M | 0 | 5.12M |
|---|---|---|---|
| 2015 | 59.42M | -1.15M | 96.73M |
| 2016 | -55.31M | 31.88M | 183.22M |
| 2017 | -70.09M | -8.31M | 2.60M |
| 2018 | -96.23M | -2.77M | 315.93M |
| 2019 | 56.67M | 1.32M | 430.98M |
| 2020 | -238.36M | -541.17M | 1.01B |
| 2021 | 538.97M | -1.03B | 250.94M |
| 2022 | -495.74M | -258.65M | 38.59M |
| 2023 | -260.37M | 374.64M | 62.66M |
CRSP Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 224.06M | 939.94M | 1.18B | 948.81M | 459.81M | 242.91M | 315.52M | 155.96M | 945K | 361K |
Operating activities | ||||||||||
Net income | -153.61M | -650.17M | 377.66M | -348.86M | 66.85M | -164.98M | -68.35M | -23.20M | -25.82M | -6.8M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 19.83M | 24.17M | 17.95M | 9.18M | 4.72M | 3.51M | 3.02M | 925K | 127K | 38K |
Stock-based compensation expense | 81.02M | 97.94M | 102.39M | 66.01M | 44.05M | 0 | 18.87M | 10.84M | 3.68M | 695K |
| Deferred income tax benefit | 81.02M | 97.94M | 102.39M | 66.01M | 44.05M | 0 | 18.87M | 10.84M | 3.68M | 695K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -200M | 305K | -161K | -45K | -11K | 2.53M | 531K | -2.81M | -339K | 0 |
Inventories | 23.32M | 0 | -37.51M | -25.74M | -5.02M | 332.29M | -551.29M | -1.08M | 0 | 0 |
Accounts payable | -20.24M | 5.16M | 37.51M | 25.74M | 5.02M | -323.28M | 546.62M | 3.86M | 0 | 0 |
Cash generated by operating activities | -260.37M | -495.74M | 538.97M | -238.36M | 56.67M | -96.23M | -70.09M | -55.31M | 59.42M | -4.79M |
Investing activities | ||||||||||
Purchases Of Investments | -1.06B | -1.41B | -1.50B | -593.99M | 0 | 0 | -500K | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -9.47M | -37.18M | -81.70M | -18.35M | -6.68M | -2.77M | -7.81M | -3.01M | -1.15M | 0 |
Acquisitions Net | 0 | 221.46M | 953.72M | 522.81M | 8.00M | 0 | 0 | -100K | 0 | 0 |
Cash generated by investing activities | 374.64M | -258.65M | -1.03B | -541.17M | 1.32M | -2.77M | -8.31M | 31.88M | -1.15M | 0 |
Financing activities | ||||||||||
Common Stock Issued | 32.72M | 970K | 250.94M | 982.28M | 415.01M | 307.05M | 2.60M | 89.06M | 58.49M | 22K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | -57K | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38.23M | 0 |
Cash used in financing activities | 62.66M | 38.59M | 250.94M | 1.01B | 430.98M | 315.93M | 2.60M | 183.22M | 96.73M | 5.12M |
Net Change In Cash | 177.00M | -715.88M | -245.52M | 236.65M | 489M | 216.9M | -75.76M | 159.55M | 155.01M | 584K |
Cash at end of period | 401.06M | 224.06M | 939.94M | 1.18B | 948.81M | 459.81M | 239.75M | 315.52M | 155.96M | 945K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |